Clearance of human papillomavirus in women treated for cervical dysplasia

Obstetrics and Gynecology

Volumn 117, Issue 1, 2011, Pages 101-108

  Moore, Elya E ^a,b   Danielewski, Jennifer A ^a,b   Garland, Suzanne M ^a,b   Tan, Jeffrey ^a,b   Quinn, Michael A ^a,b   Stevens, Matthew P ^a,b   Tabrizi, Sepehr N ^a,b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; COLPOSCOPY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 53; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 89; HUMAN TISSUE; LASER SURGERY; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA; VIRAL CLEARANCE; WART VIRUS;

ADULT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; UTERINE CERVICAL DYSPLASIA; YOUNG ADULT;

EID: 78650777046     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182020704     Document Type: Article

References (31)

1. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002;325:572.
2. Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349:978-80.
3. Costa S, De Simone P, Venturoli S, Cricca M, Zerbini ML, Musiani M, et al. Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization. Gynecol Oncol 2003;90:358-65.
4. Distefano AL, Picconi MA, Alonio LV, Dalbert D, Mural J, Bartt O, et al. Persistence of human papillomavirus DNA in cervical lesions after treatment with diathermic large loop excision. Infect Dis Obstet Gynecol 1998;6:214-9.
5. Mitchell MF, Tortolero-Luna G, Cook E, Whittaker L, Rhodes-Morris H, Silva E. A randomized clinical trial of sryotherapy, laser vaporization, and loop electrosurgical excision for the treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol 1998;92:747-4.
6. National Cancer Screening Program. Screening to prevent cervical cancer: guidelines for management of asymptomatic women with screen detected abnormalities. Canberra (Australia): National Health and Medical Research Council; 2005.
7. Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Campo E, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol 2006;103:631-6.
8. Bais AG, Eijkemans MJ, Rebolj M, Snijders PJ, Verheijen RH, van Ballegooijen M, et al. Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/ recurrent disease. Int J Cancer 2009;124:889-95.
9. Brismar S, Johansson B, Borjesson M, Arbyn M, Andersson S. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol 2009;201:17 e1-8.
10. Kim YT, Lee JM, Hur SY, Cho CH, Kim YT, Kim SC, et al. Clearance of human papillomavirus infection after successful conization in patients with cervical intraepithelial neoplasia. Int J Cancer 2010;126:1903-9.
11. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006;15: 908-14.
12. Kreimer AR, Katki HA, Schiffman M, Wheeler CM, Castle PE, ASCUS-LSIL Triage Study Group. Viral determinants of human papillomavirus persistence following loop electrical excision procedure treatment for cervical intraepithelial neo-plasia grade 2 or 3. Cancer Epidemiol Biomarkers Prev 2007;16:11-6.
13. Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000;79:294-9.
14. Sarian LO, Derchain SF, Pitta Dda R, Morais SS, Rabelo-Santos SH. Factors associated with HPV persistence after treatment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ). J Clin Virol 2004;31:270-4.
15. Venturoli S, Ambretti S, Cricca M, Leo E, Costa S, Musiani M, et al. Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J Med Virol 2008;80:1434-40.
16. Bar-Am A, Gamzu R, Levin I, Fainaru O, Niv J, Almog B. Follow-up by combined cytology and human papillomavirus testing for patients post-cone biopsy: results of a long-term follow-up. Gynecol Oncol 2003;91:149-53.
17. van Ham MA, van Hamont D, Bekkers RL, Bulten J, Melchers WJ, Massuger LF. High-risk HPV presence in cervical specimens after a large loop excision of the cervical transformation zone: significance of newly detected hr-HPV genotypes. J Med Virol 2007;79:314-9.
18. Houfflin Debarge V, Collinet P, Vinatier D, Ego A, Dewilde A, Boman F, et al. Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. Gynecol Oncol 2003;90: 587-92.
19. Bae JH, Kim CJ, Park TC, Namkoong SE, Park JS. Persistence of human papillomavirus as a predictor for treatment failure after loop electrosurgical excision procedure. Int J Gynecol Cancer 2007;17:1271-7.
20. Screening to prevent cervical cancer: guidelines for the management of women with screen detected abnormalities [rescinded]. Canberra (Australia): National Health and Medical Research Council. 1994.
21. Stevens MP, Garland SM, Tan JH, Quinn MA, Petersen RW, Tabrizi SN. HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol 2009; 81:1283-91.
22. Stevens MP, Rudland E, Garland SM, Tabrizi SN. Assessment of MagNA pure LC extraction system for detection of human papillomavirus (HPV) DNA in PreservCyt samples by the Roche AMPLICOR and LINEAR ARRAY HPV tests. J Clin Microbiol 2006;44:2428-33.
23. Coutlée F, Rouleau D, Petignat P, Ghattas G, Kornegay JR, Schlag P, et al. Enhanced detection and typing of human papillomavirus (HPV) DNA in anogenital samples with PGMY primers and the Linear array HPV genotyping test. J Clin Microbiol 2006;44:1998-2006.
24. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlée F, Hildesheim A, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-61.
25. Stevens MP, Garland SM, Tabrizi SN. Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test. J Clin Microbiol 2008; 46:3813-6.
26. Stevens MP, Tabrizi SN, Quinn MA, Garland SM. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial or cervical cancer in Melbourne, Australia. Int J of Gynecol Cancer 2006;16:1017-24.
27. Stevens MP, Garland SM, Tabrizi SN. Development and validation of a real-time PCR assay specifically detecting human papillomavirus 52 using the Roche LightCycler 480 system. J Virol Methods 2008;147:290-6.
28. Royston P. PTREND: Stata module for trend analysis for proportions. London (UK): MRC Clinical Trials Unit; 2002.
29. Chan BK, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol 2009;200:422e1-9.
30. Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst 2009;101:721-8.
31. Insinga RP, Dasbach EJ, Elbasha EH, Liaw KL, Barr E. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev 2007;16:709-15.